Tirzepatide vs. Mounjaro vs. Zepbound: Are They the Same Drug?

If you have spent any time researching GLP-1 medications, you have probably seen the names tirzepatide, Mounjaro, and Zepbound used almost interchangeably. Then you found compounded tirzepatide and wondered whether it is the same thing, a knockoff, or something else entirely. The confusion is understandable, and the distinction actually matters both medically and legally. Let's work through it clearly.

The Active Molecule Is the Same Across All Three

Tirzepatide is a molecule. It is a dual agonist that activates two receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Activating both receptors together appears to produce stronger appetite suppression and metabolic effects than activating GLP-1 alone, which is how older medications like semaglutide work.

Mounjaro and Zepbound are brand names that Eli Lilly markets for the same tirzepatide molecule. The difference is the FDA-approved indication on the label. Mounjaro was approved in 2022 for type 2 diabetes management. Zepbound was approved in 2023 for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. Same molecule, same manufacturer, different labeled use.

• Tirzepatide: the active ingredient, a dual GLP-1 and GIP receptor agonist developed by Eli Lilly
• Mounjaro: Eli Lilly's FDA-approved brand for tirzepatide indicated for type 2 diabetes
• Zepbound: Eli Lilly's FDA-approved brand for tirzepatide indicated for chronic weight management
• Compounded tirzepatide: tirzepatide prepared by a US-licensed compounding pharmacy under a valid prescription — not an FDA-approved finished drug product

What the Clinical Evidence Actually Shows for the Tirzepatide Molecule

The weight-loss data that you have probably seen cited in headlines comes from the SURMOUNT clinical trial program. In SURMOUNT-1, published in the New England Journal of Medicine by Jastreboff et al. in 2022, adults with obesity who received 15 mg of tirzepatide weekly lost a mean of approximately 20.9 percent of their body weight over 72 weeks. To put that in concrete terms: a 220-pound person losing 20.9 percent would lose roughly 46 pounds. That is not a trivial number.

More recently, SURMOUNT-5 compared tirzepatide directly against semaglutide 2.4 mg (Wegovy) in a head-to-head trial. Tirzepatide produced approximately 20.2 percent mean body-weight loss versus 13.7 percent for semaglutide. This was the first large randomized trial to put the two molecules side by side, and tirzepatide's dual-receptor mechanism appears to account for the difference.

If you have ever regained weight after a successful diet and blamed yourself, there is a relevant piece of biology worth knowing. Research from Fothergill et al. (2016), following contestants from The Biggest Loser, found that metabolic adaptation persists for years after significant weight loss. Your body defends its prior weight by lowering resting metabolic rate and increasing hunger hormones. This is not a character flaw. It is a documented physiological response. Tirzepatide works partly by overriding some of these adaptive signals at the receptor level.

How Compounded Tirzepatide Is Different From Mounjaro and Zepbound

This is the part that often gets misrepresented online, so it is worth being precise. Compounded tirzepatide is not manufactured by Eli Lilly and is not an FDA-approved finished drug product. It is prepared by a US-licensed compounding pharmacy from pharmaceutical-grade active pharmaceutical ingredient (API) under a prescription written by a licensed provider.

Compounding pharmacies operate under state pharmacy board oversight and, for sterile injectables, under FDA oversight as well. 503A pharmacies compound for individual patients with a valid prescription. 503B outsourcing facilities can produce larger batches and are subject to current good manufacturing practice (cGMP) regulations similar to drug manufacturers. The compounded product has not gone through the same FDA review process as Mounjaro or Zepbound. That is a real and meaningful distinction you deserve to understand before making a decision.

StaveMD does not compound or manufacture medication. If a prescription is appropriate for you, it is sent to a licensed US compounding pharmacy. You are not receiving a generic version of Zepbound or Mounjaro. You are receiving compounded tirzepatide, which contains the same active molecule but is a legally and regulatorily distinct product.

• Mounjaro and Zepbound are FDA-approved finished drug products from Eli Lilly — they have gone through the full FDA review and approval process
• Compounded tirzepatide is prepared by a licensed US compounding pharmacy under a prescription — it is not FDA-approved as a finished product
• The active molecule is the same, but the regulatory status, manufacturing oversight, and legal classification differ
• Compounded tirzepatide may be significantly more affordable when brand-name products are out of reach due to insurance coverage gaps or cost

Side Effects and Honest Limitations You Should Know

Tirzepatide's most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. In SURMOUNT-1, these were reported more frequently at higher doses and most often occurred during dose escalation. Starting low and increasing gradually is standard practice precisely to minimize these effects. Most people find that GI symptoms improve after the first few weeks at a given dose.

More serious but less common considerations include a boxed warning for thyroid C-cell tumors observed in rodent studies — the clinical significance in humans is not established, but tirzepatide is contraindicated if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Pancreatitis has been reported. A licensed provider should review your health history before any prescription is written. This is not a medication to obtain without a proper clinical evaluation.

Weight loss with tirzepatide also requires continued use to maintain results. Studies show that stopping the medication leads to weight regain in most people, which reflects the underlying biology of obesity as a chronic condition rather than a failure of the drug or the patient. That is something to factor into your planning and a conversation to have honestly with your provider.

What to Look for in a Telehealth Provider

If you have been burned by bait-and-switch pricing in telehealth before, you are not alone. A provider worth trusting should tell you the monthly cost of medication upfront, not after a paid consultation. They should have a licensed provider actually review your medical history, not just an algorithm. They should be transparent about what compounded means legally. And they should not promise you specific results, because no ethical provider can do that.

At StaveMD, pricing is listed before you commit to anything. A licensed provider reviews your intake form before any prescription is written. If compounded tirzepatide is not appropriate for you, you will be told that. The goal is a clinical decision that fits your health history, not a sale.